Amniotic Exosomes for Tissue Repair and Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cell-based therapies, such as those using mesenchymal stem cells, face challenges including inconsistency, immune rejection, and limited passages before senescence, which affects their potency and viability for treating conditions like bronchopulmonary dysplasia and exercise-induced pulmonary hemorrhage, necessitating a more reliable and consistent therapeutic approach.
Innovation Solution
The use of nano-sized amniotic exosomes released from mammalian amnion epithelial cells, which act as vesicular vehicles for cellular communication, exerting immunomodulatory, pro-regenerative, and reparative effects by activating endogenous repair mechanisms, reducing T-cell proliferation, increasing macrophage phagocytosis, and activating stem cells through the release of proteomic and genetic molecules like cytokines, miRNA, and non-coding RNAs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mesenchymal stem cells are used for therapy, then tissue repair and regeneration can be achieved, but product consistency is poor due to serial passaging and donor variability
Solution Approach 1:
The patent extracts the therapeutic function from the whole stem cell and isolates the exosomes (extracellular vesicles) as the active therapeutic component. This allows the therapeutic effect to be delivered without the complexities of cell passage, donor variability, and immune rejection associated with whole cell therapies. The exosomes can be produced from a single well-characterized cell bank and maintain consistent potency across batches.
Solution Approach 2:
The patent creates a copy of the stem cell's therapeutic function through exosomes, which carry proteomic and genetic molecules that replicate the regenerative and immunomodulatory effects of whole stem cells. This copying approach eliminates the need for serial passaging while maintaining therapeutic efficacy, as the exosomes can be produced from a master cell bank and stored for later use without losing potency.
2Loss of time
If banked mesenchymal progenitor cells are used to avoid delay, then therapy timing is improved, but potency variability between donors increases
Solution Approach 1:
The patent creates a universal therapeutic product (exosomes) that can be produced from a single donor cell line and applied to multiple different patients and conditions without donor-matching requirements. The exosomes carry a standardized cargo of proteomic and genetic molecules that provide consistent immunomodulatory and regenerative effects across different recipients, eliminating donor-to-donor variability while enabling rapid deployment.
3Duration of action of moving object
If repeated doses of stem cells are administered, then therapeutic effect is maintained, but immune rejection risk increases
Solution Approach 1:
By extracting only the extracellular vesicles (exosomes) from the stem cell, the patent removes the immunogenic cellular components (cell surface antigens, MHC molecules) that trigger immune rejection. The exosomes retain the therapeutic proteomic and genetic cargo while being less immunogenic, allowing for repeated dosing without the escalating immune rejection risk associated with whole cell therapies.
4Quantity of substance
If stem cells undergo multiple passages, then cell number increases, but senescence and epigenetic changes occur
Solution Approach 1:
The patent performs preliminary action by establishing a master cell bank from a single well-characterized donor before production begins. Exosomes are then produced from this frozen master bank without requiring further cell passaging. This preliminary freezing and storage of the master cell line allows for indefinite production of consistent exosome batches without the senescence and epigenetic drift that occur during serial cell passage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Amniotic exosomes facilitate tissue repair, regeneration, and reparation, including wound healing, neuronal protection, and the treatment of various diseases and conditions without the need for a compatible donor, reducing immune reactions and improving long-term physiological outcomes by promoting cellular maintenance and regeneration.
Implementation Method 1
a vesicular vehicle for cellular communication is identified as being released from mammalian amnion epithelial cells (AECs). The vesicles, referred to herein as 'amniotic exosomes,' are nanometer-sized extracellular vesicles (50-100 nm) derived from late endosomes and released from cell surfaces.
Implementation Method 2
The amniotic exosomes exert an effect on immune cells to reduce T-cell proliferation, increase macrophage phagocytosis and activate endogenous stem cells
Implementation Method 3
The amniotic exosomes exert an effect on immune cells to reduce T-cell proliferation, increase macrophage phagocytosis and activate endogenous stem cells
Implementation Method 4
The amniotic exosomes exert an effect on immune cells to reduce T-cell proliferation, increase macrophage phagocytosis and activate endogenous stem cells
Data Source
AI summary
The present disclosure relates generally to the methods of treatment of mammalian subjects by an enhanced cell-based therapeutic approach in order to facilitate tissue and neuronal repair, regeneration and/or reparation. Medicaments useful in the treatment of mammalian subjects and methods of production of the medicaments are also encompassed by the present disclosure.